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The novel optical, electrical, and magnetic properties of ultra-small inorganic nanoparticles make them
very attractive in diverse applications in the fields of health, clean and renewable energy, and
environmental sustainability. This article comprehensively summarizes state-of-the-art fluorescence
imaging using ultra-small nanoparticles as probes, including quantum dots, metal nanoclusters, carbon
nanomaterials, up-conversion, and silicon nanomaterials.

1 Introduction
When the size of inorganic materials is reduced to the nanoscale
range, they exhibit unusual optical, electrical, magnetic,
mechanical, and chemical properties, distinctly different from
those in their bulk analogues. For example, semiconductor
nanocrystals (usually referred to as quantum dots (QDs)) exhibit
strong size-dependence of their optical properties when their size
is smaller than the Bohr exciton radius.1 Magnetic iron oxide
nanoparticles become superparamagnetic when their size is
reduced below the critical size where they behave as individual
magnetic domains.2 Carbon nanotubes show remarkable tensile
strength,3 and graphene exhibits remarkably high electron
mobility.4 Their novel properties make these nanomaterials very
attractive in diverse applications, ranging from energy conversion
and storage to biomedical imaging. In this article, we summarize
the recent advances in ultra-small inorganic nanoparticles for
fluorescence imaging (Table 1), especially those smaller than 10
nm as they are easily taken up and excreted, and show longer
blood circulation time in comparison with larger ones.
For fluorescent materials, there are two kinds of
photoluminescence mechanisms, i.e. down conversion and up
conversion.5 The down-conversion process normally absorbs one
high energy photon and emits a low energy photon, e.g. a Stokesshift emission. In contrast, up-conversion is an anti-Stokes
process that converts the absorbed low energy light into higher
energy emission via multiple absorptions or energy transfer
processes. The fluorescence generated by both processes has long
been used in molecular imaging to visualize cell biology at many
levels.6, 7 The first fluorescence imaging could be dated back to
1924 when Policard observed red fluorescence from endogenous
porphyrins in tumours illuminated with an ultraviolet light.8 Since
then, advances in molecular biology, organic chemistry and
material science have revealed several classes of promising
probes for fluorescence imaging, which include small organic
dyes, fluorescent proteins, and fluorescent inorganic
nanoparticles.6 Compared with organic dyes and fluorescent
proteins, fluorescent inorganic nanoparticles have several distinct
advantages. For example, QDs have high absorbance, high QY,
narrow emission, large Stokes shifts, and high resistance to
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photobleaching.9 These properties render them robust for
fluorescent probes for biolabelling and bioimaging.9-12 In recent
years, other fluorescent nanomaterials, such as ultra-small metal
nanoclusters, fluorescent carbon and graphene dots, upconversion nanocrystals, and silicon nanoparticles have been
exploited as alternatives to conventional QDs. In the following
sections, we introduce these fluorescent nanomaterials from
viewpoints of preparation and functionalization to satisfy the
requirements for routine labelling and imaging of cells and
tissues. Advanced applications of fluorescent nanomaterials in
living systems as sensors for enzyme, oxygen, metal ions, and
pH, have readily been described elsewhere.13-16
For bioimaging, fluorescent nanoparticles should have watersolubility, biocompatibility, chemical- and photo-stability. They
should also have uniform size and high quantum yield (QY) for
optimized brightness, narrow and symmetric emission for
multiplexing and colour saturation, and minimized blinking for
light output stability. In the second part, we introduce the
development in synthesis and surface modification of fluorescent
QDs (especially CdSe- and CdTe based II-VI QDs) to result in
water-soluble, biocompatible and highly stable QDs with high
QY, together with their routine bioimaging applications and their
toxicity. In the third section, we describe extremely small metal
nanoclusters (usually smaller than 2 nm) as an emerging
fluorescent probes, and address the difficulties in their synthesis,
characterization, modification, and imaging application. In the
fourth part, we bring in carbon-based fluorescent nanoprobes
including carbon dots and graphene quantum dots (GQDs), which
are usually smaller than 10 nm. These carbon-based nanoprobes
have excellent biocompatibility and unique properties (e.g. both
up-conversion and down-conversion emissions). In the fifth
section, we briefly introduce lanthanide-based up-conversion
nanocrystals, which have attracted considerable attention in
recent years. Most of up-conversion nanoprobes have a large size
(>10 nm) and are out of the scope of this article. In the sixth part,
we discuss fluorescent silicon nanoparticles, which have excellent
biocompatibility and stability. In the last part, we highlight the
major challenges and perspectives of ultra-small fluorescent

nanoparticles and fluorescence bioimaging.
Table 1. Comparison of different types of fluorescent inorganic nanoparticles.
Types
QDs

Representatives Preparation
CdSe, CdTe, InP, Solvothermal and
CuInS2, CuInSe2, hydrothermal
methods
and their coreshell
nanostructures
Metal NCs Au, Ag, Cu, Pt, Pd Reduction of metal
salts or etching of
large metal
nanoparticles
Carbon-based C-dots, GQDs
Solvothermal and
materials
hydrothermal
methods

Size (nm) Advantages
< 10
Tuneable size and
fluorescence,
high QY and
relatively stable
<2

Ultra-small size,
easily taken up and
excreted.

Disadvantages
toxicity

Applications
Fluorescent labels
and sensors

sensitive fluorescence,
difficult for modification
and functionalization

Imaging of cells
and tissues.
Sensors

<10

Tunable
Instability and unclear of Fluorescent
fluorescence,
fluorescence mechanism biomarkers and
excellent
sensors
biocompatibility
UCNs
most >10, low background,
Low QY, potential toxicity Multimodal
Yb3+/Ln3+-doped Solvothermal and
few <10 large anti-Stokes
imaging agents and
NaYF4, GdYF4, hydrothermal
methods
shifts, sharp
drug carriers
and their coreemission, high
shell
nanostructures
stability, deep
penetration
Si NPs
Si
Etching annealed
<5
Small size, Ultrahigh Laborious synthesis,
Long-term imaging
SiOx, reduction of
stability
Low QY, Difficult to tune and labeling
fluorescence
SiCl4, and reaction
of Na4Si4 with
NH4Br
QDs: quantum dots; UCNs: up-conversion nanocrystals; NPs: nanoparticles; GQDs: graphene quantum dots; QY: quantum yield

2 Semiconducting Fluorescent QDs
5

2.1 Synthesis of monodisperse QDs with high QYs

Fluorescent QDs include semiconducting nanoparticles from
Groups IV (Si and Ge dots),17-20 II-VI (CdE and ZnE, E = S, Se,
and Te), III-V (InP), and I-III-VI (CuInS2, CuInSe2),21-23 in which
the II-VI QDs (especially CdSe and CdTe based QDs) have been
10 extensively investigated as prototypes of semiconductor QDs due
to their strong quantum confinement effects and high
fluorescence QYs. II-VI colloidal fluorescent QDs can be
prepared in organic solvents or aqueous solutions. Organic routes
are usually selected to prepare monodisperse and highly
15 fluorescent QDs. Discovered in 1981, QDs did not receive
intensive attention until 1993, when a breakthrough in
preparation of colloidal QDs in solution was achieved.24
Monodisperse cadmium chalcogenide (CdE, E = S, Se, and/or Te)
QDs were prepared by fast injection of a solution of
20 precursors (organometallic Cd and Se/S/Te dissolved in
trioctylphosphine (TOP)) into a high-boiling-point (~ 300 °C)
coordinating solvent trioctylphosphine oxide (TOPO). 24
These QDs had a narrow particle size distribution with 10%
standard deviation, which was reduced to 5% after size25 selective precipitation. Their fluorescent QY was about 10%.
The key in this “TOPO-TOP” approach is a burst of
nucleation which can be effectively separated from the
growth process.25 The use of highly flammable and toxic
dimethylcadmium, however, limited the applicability of this
30 approach at that time. Extensive efforts have been made to
develop and optimize this approach by using various stable
and low toxicity precursors 26 (e.g. cadmium oxide, CdO;

cadmium carboxylate, Cd(OOCR) 2; selenium oxide, SeO2,
etc.), non-coordinating solvents (e.g. 1-octadecene, ODE)
35 and
stabilizers 27
(e.g.
octyldiphenylamine
(ODPA),
diethylenetriaminepentaacetic acid (DTPA), hexadecyl amine
(HDA), etc.) to generate monodisperse QDs with high QY.
Monodisperse II-VI QDs with different sizes and shapes can
be obtained by controlling their nucleation and growth processes
40 through optimization of monomer concentration and reactivity,
molar ratio, reaction temperature, ligands, etc. (Figure 1).28-31 It
has been found that slight modification of reaction parameters
can lead to a broad variety of particle sizes and shapes. For
example, Peng et al. demonstrated that the size and size
45 distribution of CdSe dots can be manipulated by the monomer
concentration.32 At high monomer concentrations, the smaller
nanoparticles grow faster than larger ones, which results in the
size distribution being “focused”. If the monomer concentration
drops below a critical threshold, the smaller particles are depleted
50 as larger ones grow (i.e. Ostwald ripening), and the size
distribution gets broader or is “defocused”. Controlling the
nanoparticle growth kinetics can result in a narrow particle size
distribution (5% standard deviation) without the sizeselective precipitation. 32
55
It was observed that the QY increased monotonically to
the maximum value and then decreased with the growth
time. 33 Such a photoluminescence bright point indicates an
optimal surface structure/reconstruction. Use of a large Se/Cd
ratio (10/1) can result in very bright CdSe QDs with QY of
60 85% at room temperature. The high QY of these QDs is
attributed to stabilization of organic ligands on the surface. Since
these ligands can be chemically degraded and detached from the
surface, the photo- and chemical stability of the core is
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by Wang et al. 38 The high fluorescence QY and non-blinking
30 QDs make them very useful in applications requiring a
continuous output of single photons.
During the preparation of QDs, attempts to adjust the growth
kinetics of the QDs incidentally led to the development of onedimensional (1D) nanorods.29 By using very high precursor
35 concentrations and a defined admixture of alkylphosphonic acids
and trioctylphosphine oxide (TOPO), 1D and even more complex
structures such as arrows, teardrops, or tetrapods were
Figure 1. Transmission electron microscope (TEM) images
synthesized (Figure 1).30 Recently, we demonstrated that doped
and growth paths of CdSe nanocrystals with different
and undoped 1D semiconductor nanostructures can be produced
morphology. Reproduced from Ref. 30.
40 by using a lower precursor concentration in the presence of
bismuth nanoparticles.39-44 This is in contrast to the synthesis of
1D nanostructures without nanocatalysts. These nanowires
exhibited unusual optical,45, 46 electronic,47, 48 and magnetic40
properties with potential diverse applications.48, 49 The fast
45 growth process resulted in crystal twinning and defects in the
nanowires,50, 51 leading to a low fluorescence QY (< 1%) which
could be improved by more than three times through coating with
a wide-band-gap shell.52
Despite monodispersity, high QY, and stability, these QDs
50 generated in organic solvents are normally hydrophobic and
have to be modified in order to be water-soluble and
biocompatible for bioapplications. The modification leads to
the decrease in fluorescence QY, e.g. the QY of above
perfect core-shell CdSe@CdS QDs decreased from 94% to
36
55 77% after transferred into PBS solution with PEG-SH.
Figure 2. TEM images and blinking behaviour of core-shell
Therefore, direct preparation of QDs in aqueous solution has
CdSe@CdS nanoparticles: (a) 2.2 nm CdSe core with 2.4 nm
been developed almost simultaneously.
CdS shell; (b) 2.2 nm CdSe core with 0.7 nm CdS shell.
The aqueous approach was firstly adopted by Henglein et
Reproduced from Ref. 36.
al. to prepare CdS nanoclusters in 1982. 53 They also reported
sometimes severely affected. In order to improve their 60 the first example of the preparation of CdTe QDs in aqueous
luminescence and photostability, wide-band-gap shells (e.g.
solution. 54 The resultant CdTe QDs did not show
cadmium sulphide (CdS) and zinc sulphide (ZnS)) have been
fluorescence, however. Rogach et al. synthesized stable
coated onto their surface to form core-shell QDs.34, 35 Li et al.
fluorescent CdTe QDs with a QY of 3% by using thioglycerol
developed a successive ion layer adsorption and reaction
and mercaptoethanol as stabilizers. 55 Later on, many efforts
(SILAR) technique to epitaxially grow shells in a non- 65 were made to improve QD fluorescence QY by using
coordinating solvent.34 The resultant core-shell CdSe@CdS QDs
different
stabilizers
(thioglycolic
acid
(TGA);
had a QY of 40%. Xie and his co-workers further developed
mercaptopropionic acid (MPA)), precursor ratios, and
this approach to prepare CdSe-core-multishell QDs with QY
manners of heating (hydrothermal and microwave
up to 85%. 35 Recently, Chen et al. used cadmium oleate and
methods). 56 Under the optimal conditions, the QY of water octanethiol as Cd- and S-precursors, and prepared nearly 70 soluble CdTe-based QDs can reach as high as 84%, which is
perfect core-shell CdSe@CdS QDs with the highest QY
comparable to that of the above-mentioned hydrophobic QDs.
(97%) ever reported (Figure 2). 36 The slow continuous
High fluorescence QY also can be obtained by surface
precursor infusion and the relatively low reactivity of
modification of as-synthesized QDs with illumination. For
octanethiol provide optimal condition s for passivation of the
example, the fluorescence QY of CdTe QDs was drastically
CdSe surface and growth of the CdS shell. Compared with 75 improved from 8% to 85% after 28 -day illumination, due to
conventional core-shell CdSe@CdS QDs, these new QDs
the formation of the core-shell structure (i.e. CdTe@CdS)
featured significantly suppressed blinking, with an average
with the assistance of illumination. 57
fluorescence on/off time ratio of 94:6 for single large core The above water-soluble QDs were normally prepared in
shell nanocrystals (Figure 2). The blinking was gradually
strong basic solution (pH > 8), which limits their biosuppressed with increasing shell thickness. 36 In addition to 80 applications, as most biological activities take place under
Wurtzite core-shell CdSe@CdS QDs, zinc-blende core-shell
neutral-pH conditions. Adjusting the solution pH to neutral could
analogues with suppressed blinking (>95% on time) were
quench the fluorescence of the QDs. Therefore, it is of great
also prepared by Qin and co-workers.37 These zinc blende
interest to develop a novel approach for preparing highly
core-shell CdSe@CdS QDs exhibited a QY of 90%. It should
fluorescent water-soluble QDs from stable precursors under
be noted that non-blinking core-shell CdZnSe@ZnSe QDs, 85 neutral pH conditions. Recently, we have successfully
which exhibited complete suppression of blinking on the time
synthesized highly fluorescent (84% QY) mercaptosuccinic acid
scale from milliseconds to hours, were successfully prepared

Figure 3. Tunable core-shell CdTe@CdS QDs with high
stability. Reproduced from Ref. 58.
(MSA)-capped CdTe/CdS QDs using stable Na2TeO3 as the Te
source via a one-pot reaction under neutral conditions (Figure
3).58 A novelty of this approach is the use of MSA, which
exhibits the features (pKCOOH1 = 3.30, and pKCOOH2 = 4.94) of
5 both TGA (pKCOOH = 3.53) and MPA (pKCOOH = 4.32) in terms of
acidity. MSA can effectively stabilize QDs in a wider pH range
(pH = 6 – 9) with better protection because of its stronger
interactions with the surface Cd 2+ ions and its stronger steric
effects. In addition, slow decomposition of MSA-Cd complexes
10 forms a thin layer of CdS on the surface of CdTe nanocrystals,
decreasing the surface defects and leading to high fluorescence
QY. Another novelty is the use of sodium citrate as buffer. The
resultant QDs show higher fluorescence QY than those stabilized
with TGA or MPA obtained from the conventional aqueous
15 method.
They also show lower cytotoxicity at certain
concentrations due to the unique structure of MSA and the
formation of a CdS shell on the surface of the CdTe core.58
In addition to organic and aqueous routes, QDs can be
produced in living organisms. Stürzenbaum et al. demonstrated
20 that the earthworm’s metal detoxification pathway can be
exploited to produce water-soluble and biocompatible CdTe
QDs.59 This bioapproach is time-consuming (11 days), however,
and the resultant QDs have a low fluorescence QY (8%), so this
method cannot be used for large-scale preparation.

Figure 4. Preparation of sandwich-like SiO2@CdTe@SiO2
nanoparticles for cell labeling. Reproduced from Ref. 72.
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2.2 Surface modification of QDs
From the viewpoint of bioapplications, QDs should have
excellent water-solubility, biocompatibility, and stability. These
properties not only depend on their particle size, shape and
composition, but also rely on their surface structure and surface
charge. More importantly, the surface properties of QDs
determine their bio-interface interactions, cellular endocytosis
and intracellular distribution, in vivo biodistributions, metabolism,
and fate.60-63 Engineering surface of QDs therefore becomes
highly important as this process can improve these properties and
introduce additional functions.10 Medintz et al. recently
summarized the strategies for surface modification and
bioconjugation of QDs.11 One popular strategy for hydrophobic
QDs is ligand exchange, which not only transfers them from
organic solvents into aqueous solution, but also provides
functional groups for further conjugation with biomolecules.64
Small water-soluble molecules such as TGA, MPA, and

70

75

80

dihydrolipoic acid (DHLA) are often used. Unfortunately, ligandexchange can lead to a huge loss of fluorescence due to the
changes in surface properties. These small molecules cannot
prevent QDs from oxidation and degradation. Thereby a number
of polymers (e.g. polyethylene glycol (PEG), and
polyethylenimine (PEI)), proteins, peptides, and liposomes have
been adopted to coat QDs.12 Similar to small-molecule modified
QDs, these surface-coated flexible polymers and biomolecules
are less resistant to oxygen and chemicals, and have little impact
on the improvement of the photo- and chemical stability of QDs.
Therefore, organic-modified QDs still face the issues of toxicity,
instability and the loss of fluorescence, despite the significant
progress achieved in recent years.
Compared with unmodified and organically modified QDs,
QDs coated with an inorganic shell show higher stability in terms
of both chemistry and fluorescence. Silica is one of the most
popular inert materials used for surface modification, and has a
few distinct advantages,65 including: (1) a non-porous silica shell
can protect QDs from environmental damage and improve their
stability;66 (2) the silica shell can effectively inhibit the release of
toxic Cd2+ ions and thus reduce the QDs’ toxicity;66 (3) the silica
coating can provide a hydrophilic surface and functional groups
for conjugating with biomolecules.67 The silica shell can be
formed on the surface of the QDs by the Stöber method68 or the
reverse microemulsion approach.69 Both methods have their own
advantages and disadvantages, but one common challenge is the
preparation of highly fluorescent QDs@SiO2 nanoparticles with
tuneable size, as the fluorescence of QDs is drastically decreased
during silica coating.
In 2004, Nann et al. prepared single-dot@SiO2 nanoparticles
by the Stöber method.70 Yang and his co-workers prepared
similar CdTe@SiO2 nanoparticles by the reverse microemulsion
approach.69 These single-dot@SiO2 nanoparticles show a low
fluorescence QY (< 10%), however. Later on, the fluorescence
QY of CdTe@SiO2 nanoparticles was improved to 47%. In
comparison with incubated CdTe QDs (83%), nearly 40% of the
fluorescence was still lost during silica coating.71 The formation
of single-dot@SiO2 nanoparticles is attributed to the electrostatic
repulsion between QDs and silica intermediates.
In order to improve the fluorescence QY and the number of
QDs in each SiO2 nanoparticle, we successfully prepared
sandwich-like SiO2@CdTe@SiO2 (SQS) nanoparticles using a

Figure 5. (a) Size-dependence of SiO2@CdTe@SiO2
nanoparticles on tetraethyl orthosilicate (TEOS) volume; (bd) size-dependence of cytotoxicity and cell uptake.

Figure 6. (a) Structure of a multifunctional QD probe; (b)
C4-2 cells labelled with multifunctional QDs; (c) In vivo
targeted imaging using multifunctional QDs; (d) multicolour
capability of QD imaging in live mouse. Reproduced from

Reproduced from Ref. 74.

Ref. 76.

novel strategy (Figure 4).72 We started from the synthesis of the
thiol-capped SiO2 core. The surface thiol groups can tightly
anchor CdTe QDs on the surface of SiO2 nanospheres. Then, a
silica layer was coated on the SiO2@CdTe to form SQS
5 nanoparticles. During the silica coating, it is important to add an
appropriate amount of 3-mercaptopropyl-trimethoxysilane (MPS)
for pre-coating in order to get highly fluorescent sandwich-like
nanoparticles. Compared with other QDs@SiO2 nanoparticles,
our SQS nanopaticles show the highest fluorescence QY ever
10 reported (up to 61%). They also show higher stability and lower
toxicity in comparison with SiO2@CdTe nanoparticles.
During the modification of QDs, the overall particle size has to
be strictly controlled because it can dramatically influence the
nanoparticle biological behaviour, such as cell internalization,
15 tumour targeting and penetration, in vivo systemic and lymphatic
biodistribution, metabolism, and clearance. Nanoparticles with a
size of 20-60 nm have shown distinct biodistribution, tumour
penetration, and cellular tracking properties.73 Therefore, we
prepared a series of SQS nanopaticles with sizes in the range of
20 39 nm to 76 nm by controlling the reaction parameters, including
the amount and the type of silica precursor, the ratio of silica
precursor to ammonia, and the ratio of H2O to surfactant.74 These
SQS nanoparticles exhibited strong size dependence of their
stability, toxicity, and cellular uptake (Figure 5). Our findings
25 highlight the importance of controlling particle size and shell
thickness during the preparation of fluorescent QDs@SiO2 coreshell nanoparticles.
2.3 Fluorescence imaging of QDs

30

35

The earliest bioapplications of fluorescent QDs were reported in
1998.64, 67 Bruchez et al. coated core-shell CdSe@CdS QDs with
a thin layer of silica and then conjugated them with biotin.67 The
biotinylated QDs were successfully applied to label 3T3 mouse
fibroblast cells. Chan et al. used small molecule TGA to transfer
hydrophobic CdSe@ZnS QDs into water solution, and then
conjugated them with transferrin proteins.64 The authors
incubated TGA-modified QDs and transferrin-QD conjugates
with HeLa cells, respectively, and found that no QDs could be
observed inside the cell in the absence of transferrin. In contrast,

QDs were internalized into the cells in the presence of transferrin
due to the occurrence of receptor-mediated endocytosis.
Motivated by the above pioneering research, extensive
nonspecific and targeted bio-labelling and imaging have been
carried out at different levels, ranging from in vitro to in vivo
models.10-12 Nonspecific cellular labelling involves the use of
45 hydrophobic
and electrostatic interactions between surfacecapping molecules of QDs and biomolecules in the cell
membrane. Thus, their surface ligand properties and the cell type
largely determine the nonspecific adsorption and uptake of QDs.
In most cases, such nonspecific adsorption is unwanted, as this
50 reduces the selectivity and targeting efficiency. In order to
overcome nonspecific adsorption, PEG and its derivatives have
been used to modify the QD surface, as they can effectively
minimize and prevent the nonspecific interactions of QDs with
biomolecules, cells, and tissues.
55
Similar to the in vitro nonspecific adsorption of cells, nontargeted QDs can accumulate within tumours through the
enhanced permeability and retention (EPR) effect. Such passive
targeting is attributed to the leakiness of the tumour vasculature
and the poor lymphatic drainage, which enables QDs or other
75
60 nanoparticles to accumulate in tumours.
The EPR effect could
lead to more than 50 times as great nanoparticle accumulation in
tumours compared with healthy tissues. It is difficult, however, to
maximize nanoparticle accumulation through the EPR effect, as
this effect varies from tumour to tumour, and strongly depends on
75
65 the particle size and the surface charge.
In addition, the EPR
effect is not commonly observed in some types of cancers such as
gastric and pancreatic cancers.
An alternative approach is active targeting, which can be
achieved by conjugating QDs with targeting moieties such as
70 small molecules (e.g. folic acid and hyaluronic acid), peptides
(e.g. arginine-glycine-aspartic acid (RGD)), and proteins (e.g.
antibodies, antibody fragments, transferrin, etc.).12 In 2004, Gao
and colleagues reported a landmark work on in vivo cancer
targeting with QDs (Figure 6). 76 They first encapsulated
75 hydrophobic CdSe@ZnS core-shell QDs with an ABC triblock
copolymer
(i.e.
polybutylacrylate-polyethylacrylatepolymethacrylic acid) by using hydrophobic-hydrophobic

40

interactions between the capping ligands of QDs and the
hydrophobic segments of the block copolymer. Then, they
conjugated tumour-targeting ligands and drug-delivery
functionalities with the polymethacrylic acid segment. The in
5 vivo study showed that these QD probes accumulated at the
tumour site through the EPR effect, and the specific antibodyantigen interactions. It is worth mentioning that passive targeting
is much slower and less efficient than active targeting.
Although targeted nanoparticles hold much promise, and the
10 concept was introduced more than 30 years ago, none of them has
been clinically approved.75 One possible reason is the huge gap
between cost and benefit. Compared with expensive antibodies
and other targeting ligands, cost-effective small molecules such
as folic acid have been adopted. Folic acid and folate conjugates
15 can be specifically recognized by the folate receptor (FR), which
is a glycosylphosphatidylinositol-anchored protein. The alpha
isoform of FR (FR-α) is found to be overexpressed in many
epithelial cancers, but not highly expressed in normal tissues
except for the kidney. Since the affinity of FR to folic acid and
20 folate conjugates is relatively high (Kd ≈ 100 pM), FR-α has been
extensively investigated for tumour targeting,77 including many
studies focusing on QDs. For example, folic acid was conjugated
to PEG and subsequently deposited onto N-acetyl-L-cysteine
(NAC)-stabilised CdTeS QDs, which was demonstrated to be
78
25 able to target tumours in mouse models.
Another small targeting
molecule is hyaluronic acid, which is widely distributed
throughout connective, epithelial, and neural tissues. Hyaluronic
acid, associated with tumour angiogenesis and progression,79 has
been conjugated to QDs for tumour targeting, as it can
30 specifically
bind with CD44, a cell-surface glycoprotein
overexpressed in many tumour types. Therefore their conjugates
have not only cancer targeting characteristics, but also the
capability for imaging lymphatic vessels. 80
In addition to the high cost, the low targeting efficacy and the
35 unclear mechanism could also limit their clinical applications.
This is because not all cancer cell types overexpress the same
unique receptors, and the overexpressed receptors are often
present on normal cells.75 Moreover, the density of the targeted
receptors on tumour cells could be another factor influencing the
40 targeting efficacy. For II-VI QDs, the biggest challenge for their
clinical applications is their potential toxicity, as discussed in the
following section.

toxicity (Figure 5).74 Some research has shown that the release of
Cd2+ and the oxidation products of anions are responsible for
66
60 their bio-toxicity.
The QDs themselves (i.e. non-degraded QDs)
are not acutely toxic, and they can be retained in the body for two
years and remain fluorescent.
In 2007, Choi and co-workers studied the renal clearance of
QDs.83 They chose cationic, anionic, zwitterionic, and neutral
65 molecules to modify CdSe@ZnS core-shell QDs and tested their
binding with serum proteins. They found that the QD surface
charge has a profound effect on the adsorption of serum proteins
and the hydrodynamic diameter. Cationic or anionic charge led to
the hydrodynamic size increasing from around 5 nm to over 15
70 nm after incubation with serum. Neutral (PEGylated) QDs did not
aggregate, but had a large size. Zwitterionic coatings prevented
serum protein adsorption and produced the smallest
hydrodynamic size. The biodistribution results show that a final
hydrodynamic diameter < 5.5 nm resulted in rapid and efficient
75 urinary excretion and elimination of QDs. In their later report, the
authors conjugated small targeting molecules on the surface of
zwitterionic coatings of QDs.84 These targeted probes were also
cleared by the kidneys when their hydrodynamic size was smaller
than 5.5 nm, which sets an upper limit of 5–10 ligands per QD for
80 renal
clearance. The animal models demonstrated their
performance for in vivo targeted imaging and renal clearance
within 4 h post-injection.
Recently, Ye et al. injected phospholipid micelle-encapsulated
CdSe/CdS/ZnS QDs into rhesus macaques, and tracked the
85
85 relevant markers in the next 90 days.
Their results demonstrated
that the acute toxicity of these QDs in vivo is minimal.
Accumulation of an initial dose of Cd was found in the liver,
spleen, and kidneys, however, even after 90 days, indicating slow
breakdown and clearance of the QDs. Although QDs have not
90 shown acute or short-term toxicity, comprehensive assessments
of their long-term bio-toxicity are needed to confirm the ultimate
fate of these heavy metals and the impact of their persistence in
primates for potential clinical use.
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2.4 QD toxicity
100

Most II-VI QDs consist of toxic elements such as cadmium,
45 lead, mercury, etc. Their toxicity has always been of concern and
could limit the diversity of their applications, such as in solar
cells, light-emitting diodes, flat-screen televisions, and
biomarkers.81 The bio-toxicity depends on multiple factors,82
which can be mainly classified into two groups: (1) the inherent
50 properties of QDs, including QD size, charge, composition,
concentration, and outer-layer coating bioactivity (capping
material, functional groups); (2) environmental factors such as
oxidation, photolysis, and mechanical effects. A number of
studies show that appropriate surface modification, modulating
55 the surface charge, and controlling the QD dosage can effectively
reduce QD cytotoxicity. Previously, we demonstrated that coating
QDs with silica shells can improve their stability and reduce the
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3 Fluorescent metal nanoclusters
Since QDs have potential toxicity and long in vivo retention time,
many efforts have been made to develop alternatives to them. An
alternative is fluorescent metal nanoclusters, which have attracted
considerable attention during the past several years. It is well
known that large nanoparticles of metals such as Au, Ag, and Cu
possess the face-centred cubic (fcc) structure and the surface
plasmon resonance (SPR) property.86 Their SPR absorption is due
to the collective oscillation of electrons on the surfaces, and it is
strongly dependent on the particle size. When that size is smaller
than the electron mean path (e.g. 20 nm for Au nanoparticles), the
conducting electrons in the ground states and excited states are
confined.86 The large metal nanoparticles have very low
fluorescence emission. Very interestingly, when their size is
further reduced below 2 nm, the ultra-small nanoclusters possess
different crystal structures and exhibit strong photoluminescence
while their unique SPR property disappears.
Nanoclusters bridge the gap between molecules and
nanoparticles, and could simultaneously display the properties of
both molecules and nanoparticles. Their novel optical, electronic,

5

and catalytic activities make them very useful in ultrasensitive
detection, biolabelling, bioimaging, and catalysis.87-90 The big
challenge, however, is how to controllably synthesize metal
nanoclusters with defined size, composition, crystal structure, and
surface properties.88, 91
3.1 Synthesis of fluorescent metal nanoclusters

Compared with large nanoparticles, metal nanoclusters are
difficult to synthesize and functionalize because they only consist
of a few to tens of metal atoms. They are very sensitive to slight
10 variation of the environment, such as solution pH, ion strength,
solvents, oxygen, temperature etc. They have very high surfacearea-to-volume ratios and tend to aggregate into large particles. In
general, fluorescent metal nanoclusters can be prepared by
reduction of metal precursors or etching of large nanoparticles in
15 the presence of strong stabilizers such as small thiol-molecules,
polymers, and biomolecules.
Reduction of metal precursors such as salts and complexes is a
straightforward way to produce fluorescent metal nanoclusters.
Au nanoclusters are usually chosen as representative for
20 investigation
due to their high chemical stability, easy
preparation, and biocompatibility. The first observation of Au
photoluminescence from its ingots, single-crystal slices, and
films, with a QY of 10-10, was reported by Mooradian in 1969.92
The extremely low QY did not attract any attention until
25 Wilcoxon
et al. observed fluorescence from colloidal Au
nanoparticles with a QY of 10 -5 – 10-4.93 The authors prepared
colloidal Au nanoparticles through reduction of HAuCl4 by
citrate in water, or by metallic sodium dispersion or lithium
trisamylborohydride in inverse micelles, and then used liquid
30 chromatography to fractionate the resultant Au nanoparticles.
They found that only nanoparticles smaller than 5.0 nm showed a
blue fluorescence at 440 nm under an excitation of 230 nm. Their
results suggest that ultra-small nanoclusters could exhibit strong
fluorescence.
35
A breakthrough in preparing fluorescent Au nanoclusters was
achieved by Zheng and co-workers.94-96 They synthesized a series
of Au5, Au8, Au13, Au23, and Au31 nanoclusters using
poly(amidoamine) (PAMAM) dendrimers as stabilizers. By
adjusting the molar ratio between Au3+ and PAMAM from 1:1 to
40 1:15, they tuned the emission of these Au nanoclusters from the
ultraviolet (UV) to the near infrared (NIR) range with a QY from
10% to 70%. The latter experiments, however, proved that
PAMAM dendrimers made a contribution to the solution
fluorescence. The authors also used dendrimers as ligands to
45 prepare
fluorescent Ag nanoclusters.89, 97 In addition to
dendrimers, some other polymers such as multiarm star
polyglycerol-block-poly(acrylic acid) and DHLA functionalized
PEG were used to stabilize metal nanoclusters. 98, 99
Recently, we used multidentate thioether-terminated
50 poly(methacrylic acid) (PTMP-PMAA) (Figure 7(a)) as ligand to
successfully prepare water-soluble fluorescent Au nanoclusters
through reduction of HAuCl4 with NaBH4.100 Due to the strong
steric effect, this polymer ligand has also been used to prepare
ultra-small magnetic iron oxide nanoparticles.101-104 By
55 controlling the polymer concentration and molecular weight, we
obtained a series of Au nanoclusters with emissions between 540
– 800 nm and QYs of 2.6 – 4.8%. In contrast to dendrimers, our

Figure 7. Schematic diagram of preparation of (a) polymer
ligand PTMP-PMAA; (b) photoreductive synthesis of
fluorescent Cu, Ag, and Au nanoclusters; (c) TEM image of
Au nanoclusters. Reproduced from Ref. 100 and Ref. 105.
polymer ligands did not show fluorescence, and the observed
fluorescence was only caused by the Au nanoclusters. The
60 different emissions of Au nanoclusters are attributed to their
different sizes. On the basis of this research, we prepared
fluorescent Au, Ag, and Cu nanoclusters using photoreduction
rather than chemical reduction (Figure 7(b)).105 Compared with
conventional chemical reduction, photoreduction is clean and
65 non-toxic as this method avoids the use of additional reducing
agents. The QYs of the resultant Au, Ag, and Cu nanoclusters
were 5.3%, 6.8%, and 2.2%, respectively. Using the
photoreduction method, Shang et al. also prepared very highly
fluorescent Ag nanoclusters (18.6% QY) in the presence of
106
70 poly(methacrylic acid) (PMAA).
Compared with PMAA, our polymer ligands have a stronger
steric hindrance effect. Figure 7(c) presents a typical transmission
electron microscope (TEM) image of Au nanoclusters stabilized
with PTMP-PMAA, clearly showing their ultra-small size (< 1.0
75 nm). In order to further investigate the polymer hindrance effect,
we designed three types of tridentate thioether-terminated

polymer ligands,107 i.e. poly(methyl methacrylate) (PTMPPMMA), poly(n-butyl methacrylate) (PTMP-PBMA), and poly(tbutyl methacrylate) (PTMP-PtBMA), which were used to
synthesize fluorescent Au nanoclusters through the facile
5 photoreduction method. The resultant Au nanoclusters exhibited
blue fluorescence instead of red fluorescence due to their small
particle size. Their QYs were found to be 3.8%, 14.3%, and
20.1%, respectively, which increases with increasing polymer
steric hindrance, i.e. PTMP-PMMA < PTMP-PBMA < PTMP10 PtBMA.
In addition to polymer ligands, small thiol molecules such as
glutathione, tiopronin, MPA, DHLA, phenylethylthiolate, and
thiolate α-cyclodextrin were also used to prepare fluorescent
metal nanoclusters.87, 108, 109 For example, Luo et al. used L15 glutathione as ligands to prepare Au(0)@Au(I)-thiolate core-shell
nanoclusters with a QY of 15%.109 They proposed that strong
luminescence emission is attributed to aggregation-induced
emission of Au(I)-thiolate complexes. The QYs of metal
nanoclusters stabilized by small molecules are similar to those
20 nanoclusters stabilized with polymer.
In order to improve the biocompatibility of fluorescent metal
nanoclusters, several groups used biomolecules such as
oligonucleotides, peptides, and proteins as stabilizers during
preparation.110-113 For example, the Dickson group took
+
25 advantage of the strong affinity of Ag to cytosine bases from
single-stranded DNA, and prepared very small Ag nanoclusters
using DNA as stabilizer.110 In their later report, they used DNA
microarrays for high-throughput analysis of 12-mer strands to
identify optimized sequences for Ag encapsulation, and produced
111
30 five distinct Ag emitters with QYs in the range of 16 – 34%.
Compared with single-stranded DNA, proteins have abundant
binding sites and offer better protection to metal nanoclusters.
Xie et al. prepared Au25 nanoclusters with a QY of 6.0% using
bovine serum albumin (BSA) as the stabilizer and reducing
112
35 agent.
The reduction process was induced by adjusting the
solution pH.
Similar to the QDs produced in living organisms, fluorescent
metal nanoclusters can also be formed in-situ in cells. For
example, Wang and co-workers found that fluorescent Au
40 nanoclusters were spontaneously biosynthesized by cancer cells
(human hepatocarcinoma cell line HepG2 and leukaemia cell line
562) rather than normal cells such as human embryo liver cells
(L02) when the cells were incubated with chloroauric acid
solution.114 Au nanoclusters were formed by reduction of Au45 precursor inside the cell cytoplasm and concentrated around their
nucleoli. The selective formation of fluorescent Au nanoclusters
by cancer cells can be exploited for in vivo self-bio-imaging of
tumours.

Figure 8. (A-B) Solutions of Ag7,8 and alloyed Ag7Au6
nanoclusters; (C-D) their absorption and emission spectra;
(E) alloyed Ag7Au6 nanoclusters in solution and in the solid
state under visible and UV light; (F) comparison of the
PAGE of Ag7,8 and alloyed Ag7Au6 nanoclusters.
Reproduced from Ref. 117.

stabilized Ag nanoparticles and then added them into an organic
solvent (e.g. toluene, carbon tetrachloride, diethyl ether)
containing excess MSA under magnetic stirring. A mixture of
Ag8 and Ag7 nanoclusters with red and blue-green fluorescence
was obtained. The QYs of the Ag8 nanoclusters at room
temperature and 273 K were calculated to be 0.3% and 9%,
65 respectively. The authors used a similar approach to obtain
alloyed Ag7Au6 nanoclusters (3.5% QY) by adding HAuCl4
solution into the as-etched Ag nanocluster solution (Figure 8).117
In addition to small molecules, multivalent polymers can also
be used as etching agents. Duan et al. used multivalent
70 polyethylenimine (PEI) to etch 8 nm Au nanoparticles, which
were prepared by a two-phase approach and stabilized with
dodecylamine. The resultant cluster solution surprisingly
appeared to be in an oxidized electronic state with an emission at
505 nm. The emission was blue shifted to 445 nm with a QY of
118
75 10 - 20% after reduction with NaBH4.
Similar to organic ligands, metal precursors can also induce
the etching process. For example, Lin and co-workers extracted
from
aqueous
solution
into
HAuCl4
didodecyldimethylammonium bromide (DDAB) toluene solution,
80 and then added the mixture into 5.6 nm Au solution to result in
3.2 nm particles.119 After replaced DDAB with dihydrolipoic
acid, these Au nanoparticles were further decreased to 1.6 nm and
showed a red emission around 700 nm. Their fluorescence QY
Etching of large metal nanoparticles is an alternative approach to
was 3.4% in methanol and 1.8% in water (pH = 9). Recently,
50 prepare fluorescent metal nanoclusters. The etching process can
85 Yuan et al. developed a general etching approach to prepare
be performed by adding strong ligands or precursors into the
fluorescent Au, Ag, Cu and Pt nanoclusters with a QY of 5.4%,
nanoparticle solution. For example, Muhammed et al. synthesized
6.5%, 3.5% and 4.6%, respectively. 120 They started with
fluorescent Au nanoclusters from MSA-stabilized Au
glutathione-stabilized metal nanoparticles, and then transferred
nanoparticles by etching with excess glutathione.115 The etching
the metal nanoparticles into an organic phase by taking advantage
55 process is pH-dependent and the obtained Au 8
and Au25
90 of the electrostatic interactions between negatively charged
nanoclusters have a QY of 0.015% and 0.19%, respectively. They
glutathione (carboxyl group) and positively charged
also developed an interfacial etching process to prepare
cetyltrimethylammonium bromide (CTAB). The beauty of this
116
fluorescent Ag nanoclusters.
First, they prepared MSA60
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approach is that the resultant fluorescent metal nanoclusters can
be shuttled back to the aqueous phase using hydrophobichydrophobic interactions upon addition of hydrophobic salts (e.g.
tetramethylammonium decanoate) in chloroform.
Besides these methods, microwaves and ultrasound were also
used to assist the synthesis of fluorescent metal nanoclusters in
recent years.121, 122 For example, Xu and Suslick adopted
sonochemistry to prepare fluorescent Ag nanoclusters with a QY
of 11% in the presence of PMAA.121 Shang et al. synthesized
fluorescent Au nanoclusters (2.9% QY) via a rapid microwave
assisted method.122 In all syntheses, ligands play a crucial role in
obtaining these ultra-small fluorescent metal nanoclusters. Their
ability to donate electrons drastically influences the fluorescence
intensity, i.e. the stronger the electron donating capability is, the
higher the fluorescence intensity will be. 123
3.2 Characterization and modification of fluorescent metal
nanoclusters

Metal nanoclusters can be characterized by the techniques applied
to nanomaterials and molecules. Compared with large
20 nanoparticles, metal nanoclusters have a smaller size and a
“narrower” size distribution, so that size-selective precipitation is
not suitable for their separation. They are usually fractionated by
chromatography and electrophoresis techniques, which are
usually applied to molecules. These separation methods include
25 high-performance liquid chromatography (HPLC), size exclusion
chromatography (SEC), ion exchange chromatography (IEC),
capillary electrophoresis, and polyacrylamide gel electrophoresis
(PAGE). It is still very challenging to obtain monodisperse
nanoclusters using these approaches. For example, Tsunoyama et
30 al. separated Au:SCx nanoclusters into different fractions using
gel permeation chromatography (GPC),124 and then characterized
them with laser-desorption ionization (LDI) mass spectroscopy.
The results show that each fraction had a wide distribution of Au
atoms although they were well separated with high resolution in
35 the
GPC spectrum. Negishi and co-workers synthesized
glutathione-protected Au nanoclusters and then fractionated them
into 9 fractions, with the number of Au atoms ranging from 10 to
39 by PAGE analysis.125 Among their Au nanoclusters,
Au25(SG)18 is the most stable one.
40
The size of fractionated metal clusters can be characterized by
TEM, and their molecular weight can be measured by mass
spectroscopy. In principle, their crystal structures could be
determined by X-ray diffraction (XRD). Metal nanoclusters are
less ordered, however, and their powder XRD patterns are broad.
45 In comparison with metal complexes with defined molecular
structure, it is very difficult to obtain single crystal clusters for
structural characterization. So far, most structural investigations
of metal nanoclusters are focused on “large” Au nanoclusters.91,
108, 126-128
For example, Jadzinsky et al. determined the structure
50 of a Au 102(p-mercaptobenzoic acid)44 single crystal and found a
core-shell structure,127 in the which the Au49 core is surrounded
by two groups of Au atoms. Qian and co-workers characterized
the crystal structure of Au25(SR)18 and Au38(SR)24 nanoclusters,
and found a similar core-shell structure.91 An Au25(SR)18 cluster
55 consists of an icosahedral Au 13 core and exterior 12 Au atoms in
the form of six –RS–Au–RS–Au–RS– motifs.91, 108

Figure 9. (a) Kohn-Sham orbital energy level diagram for a model
compound Au25(SH)18; (b) Solid-state model for the origin of the
two luminescence bands in (d); (c) theoretical absorption spectrum
of Au 25(SH) 18; (d) two luminescence peaks observed in Au 28(SG) 16

clusters. Reproduced from Ref. 131 and Ref. 132.

The ultra-small size (limited atomic numbers) of metal
nanoclusters makes it possible to predict their crystal structures
through precise theoretical simulation. For example, Xiang et al.
60 developed a new genetic algorithm approach to search for the
global lowest-energy structures of DMSA-stabilized Ag
nanoclusters.129 In combination with density functional theory
(DFT), their genetic algorithm simulations show that the ground
state of [Ag7(DMSA)4]− has eight instead of four Ag−S bonds,
65 with a much lower energy than the structure based on the
[Ag7 (SR)4 ]− cluster with a quasi-two-dimensional Ag7 core. Their
simulated X-ray diffraction pattern of the [Ag7(DMSA)4]− cluster
is in good agreement with the experimental results.
The optical properties of fluorescent metal nanoclusters can be
70 characterized
with UV-visible (UV-Vis) absorption and
photoluminescence spectroscopy. As mentioned previously,
metal nanoclusters have no SPR absorption, but they show
molecular-like electronic transitions due to the quasi-continuous
energy band structure and quantum confinement effects. Bakr et
75 al. synthesized Ag nanoclusters through the reduction of Agprecursor in the presence of 4-fluorothiophenol,130
and
investigated the evolution of their absorption from multiple bands
into a single SPR band by heating the original nanocluster
solution at 90 ˚C for different periods of time. Their results
80 demonstrate the size dependence in UV-Vis absorptions of metal
nanoclusters.
In order to demonstrate the origin of multiband absorption,
Zhu and co-workers chose the Au25(SR)18 cluster as a model and
simulated their absorption by performing time-dependent DFT
131
85 calculations.
Figure 9(a) shows the Kohn-Sham molecular
orbitals, energies, and atomic orbital contributions in the cluster.
The highest occupied molecular orbital (HOMO) and the lowest
three lowest unoccupied molecular orbitals (LUMOs) are mainly
composed of 6sp atomic orbitals of Au, and these orbitals
90 constitute the sp-band. The HOMO-1 to HOMO-5 orbitals are
constructed from the 5d atomic orbitals of Au and form the dband. In addition, the s 3p orbitals make contributions to both sets
of HOMO and LUMO orbitals. The multiband absorption of

metal nanoclusters suggests their multiple emission peaks and
broad fluorescence spectra (Figure 9(b)). Figure 9(c) shows the
simulated absorption spectrum. The multiple absorptions are
attributed to the intraband (sp) HOMO → LUMO transition, the
5 interband transition (d → sp), or mixed sp → sp intraband and d
→ sp interband transitions.131 Figure 9(d) shows two fluorescence
bands with the maxima at around 1.5 and 1.15 eV observed in
Au28(GSH)16 nanoclusters by Link et al.132 These two bands are
separated from a broad luminescence in the range of 2.0 – 0.8 eV,
10 and are ascribed to the radiative interband recombination between
the sp and d bands, and intraband transitions (sp bands) between
the HOMO and LUMO.
Despite the good agreement between simulated data and
experimental observations, the origin of metal fluorescence is not
15 completely
understood. Most reported atomically precise
Au n(SR)m nanoclusters show very weak luminescence. Recently,
Yu and co-workers identified that Au22(SR)18 has two RS-[AuSR]3 and two RS-[Au-SR]4 motifs that are interlocked and
capped on a prolate Au8 core.133 These Au22(SR)18 nanoclusters
20 exhibited an emission at ∼665 nm with a QY of ∼8%. Their
results show that the luminescence of these core-shell
nanoclusters was generated by the aggregation-induced emission
of Au(I)-thiolate complexes on the nanocluster surface.
The fluorescence of metal nanoclusters is very sensitive to the
25 cluster size, surface ligands, solvents, etc., so it is thus necessary
to modify them in order to maintain their bright fluorescence in
addition to improving their stability and biocompatibility. There
are few reports, however, on the post-modification of fluorescent
metal nanoclusters in comparison with large nanoparticles, due to
30 their tiny size and sensitivity to external conditions. Lin and coworkers prepared DHLA-protected fluorescent Au nanoclusters
by etching large nanoparticles and replacing surface ligands.119
They took advantage of carboxylic acid groups from DHLA to
conjugate PEG–NH2 or biotin-PEG–NH2 with Au nanoclusters.
35 The gel electrophoresis and the cell labelling indicate the
successful conjugation. Samanta et al. prepared fluorescent Au
nanoclusters using a novel quaternary ammonium as the ligand,
and then coated them with silica.134 Similar to fluorescent QDs,
surface modification can lead to the fluorescence quenching of
40 metal nanoclusters. It is still a great challenge to obtain robust
fluorescent metal nanoclusters through surface modification.
3.3 Application of fluorescent metal nanoclusters in bioimaging
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Similar to other fluorophores, fluorescent metal nanoclusters have
also been tested for in vitro and in vivo bioimaging. In the early
reports, Zheng et al. prepared fluorescent Au, Ag nanoclusters in
the presence of dendrimers, DNA, and proteins, and used them as
labels for cell imaging.89, 94-97 Baskov et al. prepared fluorescent
Ag nanoclusters in the presence of thioflavin T with remarkable
fluorescent properties,135 and then used them to label amyloid
fibrils produced from recombinant mammalian prion proteins and
non-prion proteins. The labelled amyloid fibrils exhibited a timedependent increase in fluorescence with no photobleaching after
24-h illumination, while those stained with thioflavin T showed a
rapid decay in fluorescence. Their results demonstrate the higher
stability of Ag nanoclusters than that of organic fluorophore.
Recently, we prepared fluorescent Au nanoclusters stabilized
with PTMP-PMAA, and then compared them with CdTe QDs in

Figure 10. Comparison of cell labeling by using fluorescent
Au nanoclusters and CdTe QDs. Reproduced from Ref. 100.
labelling suspended and adherent hematopoietic relatively normal
cord blood mononuclear (CBMC) cells and cancer K562 cells
100
60 (Figure 10).
The results show that the cancer cells took up
more Au nanoclusters than the normal cells, even though they
were from the same hematopoietic system. There was no
difference, however, in the uptake of CdTe QDs between the two
kinds of cells. The selective uptake of Au nanoclusters by cancer
65 cells could be attributed to the unique properties of Au
nanoclusters or the nature of the cells. In addition, CdTe QDs
destroyed the nuclei of some cells. We also compared the
cytotoxicity of Au nanoclusters with that of CdTe QDs through
MTT and apoptosis assay. The results show that our fluorescent
70 Au nanoclusters had lower toxicity than QDs, and did not induce
acute toxicity. These advantages make them very attractive in
selective bio-labelling of cancer cells. Retnakumari et al.
conjugated folic acid with BSA-stabilized Au nanoclusters and
then used them for targeted imaging. 136 The receptor-targeted
+ve
75 cancer detection was demonstrated on FR
oral squamous cell
carcinoma (KB) and breast adenocarcinoma MCF-7 cells, where
the FA-conjugated Au25 clusters were found to be internalized in
significantly higher concentrations compared to the negative
control cell lines.136 Apart from routine utilization of cell
80 labelling,
fluorescent metal nanoclusters can be used as
intracellular sensors. For example, Shang and co-workers
demonstrated the use of Au nanoclusters for intracelluar
thermometry by taking advantage of the temperature sensitivity
of their fluorescence lifetime and emission intensity (Figure

Figure 11. FLIM images of HeLa cells with internalized Au
nanoclusters at four different temperatures. Reproduced from
Ref. 15.
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11).15 Using fluorescence lifetime imaging microscopy (FLIM),
they observed the considerable variation of fluorescence lifetime
of nanoclusters internalized in HeLa cells with the temperature
increasing from 15 to 45 ˚C.
In addition to the above in vitro cell labelling and imaging, Wu
et al. investigated in vivo imaging through the tail vein
administration of near infrared (NIR) fluorescent Au nanoclusters
in live mice,137 and found that the uptake of NIR Au nanoclusters
by the reticuloendothelial system was relatively low in
comparison with other nanoparticles due to their ultra-small
hydrodynamic size (~2.7 nm). They then used MDA-MB-453 and
xenografted HeLa tumour cells as models to do in vivo and ex
vivo imaging studies, and found that the ultra-small Au
nanoclusters were highly accumulated in the tumour areas due to
the enhanced permeability and retention (EPR) effect. 137
Zhou and co-workers studied the renal clearance of 2 nm
glutathione (GSH)-coated fluorescent Au nanoclusters (Figure
12),138 and found that only ~4% of the particles were accumulated
in the liver, while more than 50% of the particles were found in
urine within 24 h after intravenous injection, which is comparable
to the QDs with the best renal clearance efficiency.83 They also
used computed tomography (CT) to visualize real time
accumulation of luminescent GS-AuNPs in the bladder, and
demonstrated that fluorescent Au nanoclusters can serve as
contrast agents for CT imaging (Figure 12). Recently, they
compared GSH-coated fluorescent Au nanoclusters (2.5 nm) with
small dye molecules IRDye 800CW,139 and found that they both
have similar physiological stability and renal clearance, but Au
nanoclusters exhibited a much longer tumour retention time and
faster normal tissue clearance (Figure 12). These merits enabled
the Au nanoclusters to detect the tumour more rapidly than the
dye molecules without severe accumulation in reticuloendothelial
system organs.139
Besides the above in vivo passive targeting, fluorescent metal
nanoclusters can be tagged with bioactive molecules for targeting,
imaging, and therapy. For example, Liu et al. synthesized
fluorescent Au nanoclusters (0.92 ± 0.03 nm) using insulin as a
template.113 The resulting Au-insulin nanoclusters retain the
insulin bioactivity and biocompatibility, and have been used to
regulate the in vivo glucose level in Wistar rats. The results show

Figure 12. (a) Biodistibution of 2-nm GS-Au nanoclusters.
The inset shows CT images of a live mouse before and 30
min after injection of Au nanoclusters; (b-d) comparison of
biodistribution of GS-Au nanoclusters and IRDye 800CW.
Reproduced from Ref. 138 and Ref. 139.
that an injection of insulin-Au nanoclusters into the rats tended to
reduce the blood glucose in a similar way to commercial insulin.
Fluorescent insulin-Au nanoclusters can also be used as contrast
agents for CT imaging.113 These studies indicate that ultra-small
45 fluorescent Au nanoclusters could simultaneously serve as very
promising contrast agents for in vivo fluorescence imaging and
CT imaging.
In summary, fluorescent metal nanoclusters as emerging
fluorophores have attracted considerable attention due to their
50 tuneable emissions, ultra-small size, fast renal clearance, and low
toxicity. There are a few obstacles to be overcome, however,
including (i) low fluorescence QY, which is usually about ~10%
and less than that of QDs and many organic dyes; (ii)
polydispersity in size and components, which makes it very
55 difficult to fundamentally study their novel properties and
mechanisms; (iii) difficulty in modifying their surface to
introduce other functions due to their tiny size and lower stability;
(iv) complicated interactions with biological environments.

60

4 Fluorescent carbon nanomaterials
4.1 Fluorescent carbon dots

Fluorescent carbon dots are also used as alternatives to QDs for
bioimaging,17, 140 because they not only exhibit several favourable
attributes of traditional semiconductor-based QDs (namely, size65 and
wavelength-dependent
emission,
resistance
to
photobleaching, ease of bioconjugation), but also show chemical
inertness, low toxicity, and biocompatibility. Fluorescent carbon
dots were accidently discovered in 2004 during the purification of
single-wall carbon nanotubes (SWCNTs) fabricated by the arc141
70 discharge approach.
Two new classes of nanomaterials were
isolated from the crude soot. One was short, tubular carbon, and
the other a mixture of fluorescent nanoparticles derived from the
SWCNTs.
In 2006, Sun et al. obtained 5-nm non-fluorescent carbon dots
75 via laser ablation of a carbon target, and then modified them with
PEG to get fluorescent carbon dots with a fluorescence QY of 4%
– 10%.142 The photoluminescence of these carbon dots was broad
and strongly dependent on the excitation wavelength, which
could be attributed to the different sizes in the sample and
80 different emission sites on the passivated particle surfaces. After
fractionation with gel column chromatography, most of the

Figure 14. (a) NIR images of mouse bladders acquired
before and after injection of carbon dots through intravenous
injection, subcutaneous injection, and intramuscular
injection; (b) quantification of the ZW800 fluorescence
signal in (a); (c) representative coronal images from 1 h
dynamic positron emission tomography (PET)
imaging.
Reproduced from Ref. 152.

Figure 13. Digital images of solid fluorescent carbon dots,
aqueous solutions, and their absorption, excitation and
emission spectra. Reproduced from Ref. 144.
fluorescent fractions could achieve emission yields close to
60 %.143 Interestingly, their optical properties resemble band-gap
transitions, which are found in nanoscale semiconductors,
suggesting that carbon dots have essentially semiconductor-like
5 characteristics. Recently Bhunia et al. prepared hydrophobic and
hydrophilic carbon dots with tuneable size and visible
emissions,144 by dehydrating carbohydrate in octadecene in the
presence of octadecylamine, or in concentrated sulphuric acid
(Figure 13). Their method produced gram-scale fluorescent
10 carbon dots with a QY of 6 – 30%. Zhu and co-workers also
reported a rapid and high-output hydrothermal approach to
prepare polymer-like carbon dots with QYs as high as 80 %.145
In addition to solid fluorescent carbon dots, there are some
reports on hollow fluorescent carbon dots.146, 147 For example,
15 Fang et al. simply mixed acetic acid, water and diphosphorus
pentoxide to obtain cross-linked hollow fluorescent carbon
nanoparticles. By reducing the release of heat, they also obtained
solid fluorescent nanoparticles. So far, many approaches, such as
arc-discharge, laser ablation, electrochemical oxidation,
20 combustion/pyrolysis,
and hydrothermal and microwave
methods, have been developed to prepare solid and hollow
fluorescent carbon dots.148 The preparation is inexpensive on a
large scale without the need for stringent, intricate, tedious,
costly, or inefficient steps.149 The recent advances in the synthesis
25 and characterization of fluorescent carbon dots have been
reviewed.17, 148, 149
The first study of fluorescent carbon dots in bioimaging was
reported by the Sun group in 2007.150 The authors used poly(propionylethylenimine-co-ethylenimine) (PPEI-EI, with EI
30 fraction ~20%) to modify the carbon dots, and then applied them
to label human breast cancer MCF-7 cells. These labelled cells

exhibited bright fluorescence in both cell membrane and
cytoplasm regions under an excitation of 800-nm laser pulses.
The results demonstrate that carbon dots exhibit strong
35 luminescence with two-photon excitation in the near-infrared, and
moreover,
large
two-photon
absorption
cross-sections,
comparable
to
those
of
available
high-performance
semiconductor QDs.150 The authors further demonstrated the in
vivo imaging of fluorescent carbon dots.151 They compared the
40 imaging capability of carbon dots and ZnS-doped carbon dots,
and found that the later dots emitted more strongly than the
former dots both in solution and in mice. The fluorescence from
the bladder area was observed, and 3 h after injection, the
fluorescence could be detected in the urine, but it completely
45 faded 24 h after injection. They analysed the biodistribution of
carbon dots and found that the carbon dots accumulated in the
kidney and, to a small extent, in the liver.151 This is attributed to
the surface PEG, which likely reduces the protein adsorption.
Recently Huang and co-workers investigated the effects of
50 injection routes on the biodistribution, clearance, and tumour
uptake of carbon dots (Figure 14).152 They prepared fluorescent
carbon dots through a laser ablation approach, and then
functionalized carbon dots with the NIR dye ZW-800 and the
isotope 64Cu. They injected the conjugates into mice in three
55 different
manners, i.e. intravenous, intramuscular, and
subcutaneous injection. The results show that the carbon dots
were efficiently and rapidly excreted from body after injection,
and the clearance rate of carbon dots
decreased when the
administration was varied from intravenous, to intramuscular, and
60 then to subcutaneous injection (Figure 14). Different injection
routes also showed different blood clearance patterns and
different tumour uptake of carbon dots.
4.2 Fluorescent graphene quantum dots
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It should be noted that fluorescent graphene quantum dots
(GQDs), the analogues of
carbon dots, have also attracted
considerable attention.153, 154 Similar to carbon dots, GQDs can be
prepared by top-down and bottom-up approaches, and their
fluorescence can be enhanced via surface modification. The topdown methods usually refer to cutting larger size carbon

Figure 16. Nitrogen-doped GQDs for cellular and deeptissue imaging. Reproduced from Ref. 164.
was changed into blue after the GQDs were modified with
alkylamines or reduced with NaBH4 (referred to as m-GQDs and
r-GQDs respectively), while the particle size was similar. The
fluorescence shift was attributed to the suppression of nonradiative processes and to the enhanced integrity of the π
35 conjugated system. These three types of GQDs exhibited strong
excitation-dependent down-conversion and up-conversion
emissions, demonstrated by that of the m-GQDs in Figure 15(ef),155 which is in contrast to Zhuo’s report [Figure 15(c-d)]. In
addition to the preparation, the optical properties of GQDs are
154
40 also influenced by the solution pH, solvent, and concentration.
Recently, Xu et al. studied the fluorescence of GQDs on a
substrate at the single particle level.160 All the GQDs investigated
had the same spectral lineshapes and peak positions, despite
notable differences in particle size and the number of layers.
45 GQDs with more layers were brighter than those with fewer
layers, but were associated with shorter fluorescence lifetimes.
Although there are some debates on the fluorescence
mechanisms of GQDs, their unique properties afford many
applications in cellular and deep-tissue imaging. Sun and co50 workers demonstrated the first bioapplication of nanographene
oxide (NGO),162 i.e., single-layer graphene oxide sheets a few
nanometers in lateral width. The PEGylated NGO sheets used
were soluble in buffers and serum without agglomeration, and
showed photoluminescence in the visible and infrared regions.
55 These NGO sheets had low background photoluminescence in the
near-infrared (NIR) window. In addition, simple physisorption
through π-stacking was used to load the anticancer drug
doxorubicin onto NGO functionalized with antibody for selective
162
killing of cancer cells in vitro.
60
Compared with fluorescent carbon dots, GQDs can be used for
two-photon or multi-photon luminescence imaging.163, 164 Qian et
al. used PEGylated graphene oxide nanoparticles to label HeLa
cells,163 and observed that graphene oxide nanoparticles were
mainly localized in the mitochondria, endoplasmic reticulum,
65 Golgi apparatus, and lysosomes of HeLa cells with a two-photon
scanning microscope. They intravenously injected graphene
oxide nanoparticles into mouse bodies from the tail vein, and
observed their flow, distribution, and clearance in the blood
vessels, utilizing a deep-penetrating two-photon imaging
70 technique. These nanoparticles were also injected into the brains
of gene transfected mice, and the in vivo two-photon
luminescence imaging results showed that graphene oxide
nanoparticles were located at 300 µm depth in the brain,
30

Figure 15. (a) Image of GQD solution under UV-light; (b)
schematic emissions in GQDs; (c-d) excitation-independent
down-conversion and up-conversion spectra of GQDs; (e-f)
excitation-dependent down-conversion and up-conversion
spectra of GQDs. Reproduced from Refs. 155, 157, 160, and
161.
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materials such as carbon nanotubes, graphene or graphene oxide
sheets, and carbon fibres into small GQDs, through strong acid
oxidation, hydrothermal or solvothermal treatment, or microwave
and sonication treatment.154 For example, Zhu et al. dispersed
graphene oxide in dimethyl formamide (DMF) under sonication,
and then transferred the suspension into Teflon autoclaves and
treated them at high temperature for a few hours to get GQDs
with a QY of 11%.155, 156 Tetsuka and co-workers used the
hydrothermal approach to treat graphene oxide sheets in ammonia
solution to get GQDs with a QY between ~19 – 29%.157 The
emission of GQDs can be tuned by controlling the hydrothermal
temperature (Figure 15(a)), and the QYs can be further enhanced
to ~46% after modification with PEG. Wu et al. used a one-step
pyrolysis of a natural amino acid (i.e. glutamic acid) to prepare
fluorescent GQDs with a QY of 54.5%.158 Recently, Dong and
co-workers used L-cysteine as precursor to prepare S,N-co-doped
GQDs with a QY up to 73%,159 which is the highest value
reported so far.
The preparation process significantly influences the optical
properties of GQDs. There are two types of emissions in GQDs,
i.e. intrinsic state emission and defect state emissions (Figure
15(b)).160 The competition between these two states could be
changed during preparation or post surface modification. For
example, Zhuo and colleagues oxidized graphene in concentrated
H2SO4 and HNO3, and then sonicated the mixture and calcinated
it at 350 ˚C to remove acid.161 The resultant fluorescent GQDs
did not exhibit excitation-dependent fluorescence [Figure 15(cd)].161 However, Zhu et al. prepared green fluorescent GQDs
through the hydrothermal approach.155 The green fluorescence
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demonstrating the advantage of QGDs for deep imaging in
tissues. Recently, Liu et al. prepared nitrogen-doped GQDs as
efficient two-photon fluorescent probes.164 These N-GQDs
exhibited the highest two-photon absorption cross-section (up to
48000 Göppert-Mayer units) among the carbon-based materials.
They also demonstrated a large imaging depth of 1800 µm by a
study of penetration depth in tissue phantom (Figure 16).
In
summary,
surface-modified
fluorescent
carbon
nanomaterials (carbon dots and GQDs) have small size,
distinctive photoluminescence properties, low toxicity, and low
cost. These advantages offer them great potential for optical
imaging and biomedical applications, as they might gradually
replace conventional semiconductor QDs in these aspects.
5 Ultra-small up-conversion nanocrystals

Compared with previously mentioned fluorescent nanomaterials,
up-conversion nanostructures, especially lanthanide-doped
nanocrystals, have distinct advantages in fluorescence
bioimaging, such as low autofluorescence background, large anti20 Stokes shifts, sharp emission bandwidth, high resistance to
photobleaching, and high penetration depth and temporal
resolution,165-171 In addition, they can be used for multimodal
bioimaging and therapy (Figure 17). More bioapplications of upconversion nanoparticles can be found in recent reviews.165, 169-171
25 However, they usually have a larger size in comparison with
those nanoprobes described previously (i.e. QDs, metal
nanoclusters, carbon dots, and GQDs). There are few reports on
ultra-small up-conversion nanoparticles, especially those below 5
nm.172-177 Herein we mainly introduce the fundamentals of up30 conversion nanoparticles and the progress in preparation and
imaging application of ultra-small nanoparticles.
For up-conversion nanocrystals, their emission process
involves the sequential absorption of two or more photons, which
is fundamentally different from the multi-photon process, where
35 the absorption of photons takes place simultaneously. There are
three types of up-conversion mechanisms, i.e. excited state
absorption (ESA), energy transfer up-conversion (ETU), and
photon avalanche.166 The up-conversion nanocrystals usually
consist of activators, sensitizers, and the host matrix [Figure
40 17(a)]. The activators should have more excited energy levels,
and the energy difference between each excited level and the
ground level should be close enough to facilitate photon
absorption and energy transfer in the up-conversion process.
Lanthanide ions such as Er3+, Tm3+, and Ho3+ have such ladder45 like energy levels and are usually selected as activators. In order
to improve the luminescence efficiency, sensitizers are
introduced. Yb3+ is usually chosen as sensitizer because it has
only one excited energy level (2F5/2), and the transition between
the ground level (2F7/2) and excited level is strongly resonant with
50 many f-f transitions of lanthanide ions. The concentration of
activators, and the molar ratio between activators and sensitizers
is usually kept low to avoid the quenching effect.166 Zhao et al.,
however, showed that up-conversion luminescence can be
significantly enhanced by using much higher activator
3+
55 concentrations (e.g. 8 mol% Tm
in NaYF4) under relatively
178
high-irradiance excitation.
The authors attributed the high
brightness to a combination of high excitation intensity, increased

Figure 17. (a) Schematic structure of multifunctional upconversion nanoparticles; and (b) their potential applications
in bioimaging and therapy. Reproduced from Ref. 165.
activator concentration, and accelerated sensitizer-activator
energy transfer rate arising from the decreased average minimum
60 distance between adjacent lanthanide ions. The high brightness
makes it possible to remotely track a single nanocrystal with a
microstructured optical-fibre dip sensor.178
Ideal host materials should have low lattice phonon energy and
the minimum lattice mismatch with dopants (activators and
65 sensitizers). Rare-earth fluorides are generally chosen as host
materials, as rare-earth ions have similar ionic size and chemical
properties to lanthanide ions, and their fluorides exhibit low
phonon energy and high chemical stability. 166 In particular,
NaGdF4 is extensively used as it can serve as a positive contrast
70 agent for magnetic resonance imaging (MRI). Johnson et al.
prepared four different sizes of β-NaGdF4 nanoparticles between
2.5 nm and 8.0 nm.172 They found that the longitudinal relaxivity
of nanoparticles increased from 3.0 mM-1s-1 to 7.2 mM-1s-1 with
decreasing particle size from 8.0 nm to 2.5 nm. The authors
3+
75 doped Yb
and Tm3+ into β-NaGdF4 to form 3.5 nm particles,
which exhibited an emission at 800 nm under the excitation of a
980-nm laser.172 Their results highlight the importance of
preparation of ultra-small nanoparticles in order to achieve large
relaxivity for MRI.
80
The fluorescence of up-conversion nanoparticles can be
engineered through modulation of activators, sensitizers, host
materials, and their crystal phase, particle size, and surface
coating. Hasse and co-workers demonstrated the first example of
multicolour emission of Yb3+/Er3+, and Yb3+/Tm3+ co-doped α179
85 NaYF4 colloidal solution.
In 2008, Wang et al. developed a
general and versatile approach to fine-tune the multicolour
emissions over a broad range with single wavelength
excitation.180 By introducing Gd3+ during preparation, the authors
simultaneously controlled the crystal phase, particle size, and
181
90 optical properties of the resultant nanocrystals.
Recently, a
core-shell structure with a set of lanthanide ions incorporated into
separated layers was designed. The core-shell structure can
minimize the deleterious effects of cross-relaxation. The bright
up-conversion emission was achieved through Gd 3+ mediated
95 energy
migration without long-lived intermediate energy
states.182, 183
In up-conversion nanoparticles, minimizing the depletion of
excitation energy is the key to tuning their luminescence. The
excitation energy can randomly migrate from an atom to its
100 neighbouring atoms that are isotropically distributed in a 3D
structured crystal sublattice (type I in Figure 18). This energy can
also migrate in a crystal with a 2D layer structure (type II), or in a
crystal featuring a 1D atomic chain structure (type III).184

Figure 20. Biodistribution of 5.1nm (NaGdF4) and 18.5nm
(NaGdF4:Yb,Er) nanoparticles in different organs and tissues
of mice. Reproduced from Ref. 189.

Figure 18. Schematic illustration of the topological energy
migration pathways in different types of crystal sublattice.
Reproduced from Ref. 184.
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Figure 19. Multifunctional upconversion nanoparticles for
diagnosis and treatment of cancer through imaging-guided
therapy. Reproduced from Ref. 186.
Recently, Wang et al. proposed that migration of the excitation
energy can be effectively minimized through use of a type IV
(Figure 18) lattice containing arrays of isolated atomic clusters.184
This allows to minimize the concentration quenching of the
5 luminescence, and generates an unusual four-photon-promoted
violet up-conversion emission from KYb2F7:Er (2 mol%) with an
intensity more than eight times higher than that previously
reported.184 The approach of enhancing up-conversion through
energy clustering at the sublattice level may provide new
10 opportunities to engineer up-conversion nanoparticles for diverse
applications.
The good understanding of the energy migration, luminescence
mechanism, and the recent advances in wet chemistry have
enabled the fine-tuning of particle size (even in the small size
15 range), crystal structure, surface functionalities, and optical
properties of up-conversion nanocrystals for bioimaging, drug
delivery, and sensing.165, 167, 169 Their fluorescence has been
applied to image cells and small animals.185 As mentioned
previously, Gd-based up-conversion nanoparticles are particularly
20 interesting as they can serve as fluorescent nanoprobes and
contrast agents of MRI simultaneously. Recently, a
multifunctional drug delivery system combining up-conversion
luminescence/magnetic
resonance/computer
tomography
trimodality imaging and NIR-activated platinum pro-drug
25 delivery has been developed by Dai and co-workers (Figure
19).186
Organic-soluble
core−shell
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NaYF4:Yb3+/Tm3+@NaGdF4:Yb3+ nanoparticles were first
prepared by complex thermal decomposition method, followed by
surface modification and conjugation with the trans-platinum
(IV) pro-drug. The up-conversion nanoparticles can not only
deliver the platinum (IV) pro-drugs into the cells effectively, but
convert near-infrared light into UV to activate pro-drug as well.
Meanwhile, they can further serve as contrast agents for
multimodality imaging to guide cancer treatment. The pro-drugconjugated nanoparticles under near-infrared irradiation led to
better inhibition of tumor growth than that under direct UV
irradiation in the mouse test.186 Such multifunctional upconversion nanoparticles have been a subject of intensive
research due to their potential in disease diagnosis and
treatment.165, 170
For in-vivo bioapplications, one of the major issues for upconversion nanocrystals is the fate of nanoparticles and potential
toxicity of lanthanide ions.187, 188 Liu et al. prepared 5.1 nm
NaGdF4 and 18.5 nm NaGdF4:Yb/Er nanoparticles with the same
surface modification and investigated their biodistributions in
different organs and tissues of mice (Figure 20). 189 The
accumulation of both types of nanoparticles in liver decreased
with the circulation time. In contrast, their accumulation in spleen
increased with the circulation time. This suggests that both of
these nanoparticles may be eliminated through the biliary
pathway. Analysis of urine collected at different time points
indicates that renal clearance was one of the major elimination
pathways for 5.1-nm particles, but not for 18.5-nm particles.
Further analysis on faces by TEM shows that these particles do
not change in shape and size, suggesting the high stability of upconversion nanoparticles in vivo.189
Although up-conversion nanoparticles do not show acute
toxicity at the cell or animal level, it is necessary to investigate
their long-term toxicity. Another drawback of up-conversion
nanocrystals is the low quantum yield (usually less than 1%) in
comparison with other fluorescent agents. 165 Preparation of
highly efficient up-conversion nanocrystals remains a great
challenge.
6 Fluorescent silicon nanoparticles
Fluorescent silicon nanoparticles (Si NPs) have also attracted
considerable attention in bioapplications due to their excellent
biocompatibility as silicon naturally exists in human body as a

Figure 21. (a) Silicon nanoparticle fractions under ambient
light and under photoexcitation at 365 nm; (b-c) sizedependent absolute QYs of Si nanoparticles. Reproduced
from Ref. 191.
trace element.18, 20, 190 More importantly, they have tunable
fluorescence from visible to near-infrared window. Compared
with other semiconducting QDs, the preparation of high-quality
water-soluble and biocompatible Si QDs is devious and
5 laborious. Colloidal Si NPs are conventionally prepared by
etching annealed SiOx
with HF, plasma approach,
electrochemical method, laser ablation, reduction of SiCl4, and
solvothermal reaction of sodium silicide with NH4Br.18, 190-193
These Si NPs are usually functionalized with hydrophobic ligands
10 such as styrene, alkyl, and octene. They are photochemically
stable in non-polar solvents up to 1 year.192 For example, hightemperature thermal processing of the sol-gel precursor derived
from trichlorosilane (HSiCl3) produced Si NPs embedded within
the SiO2 matrix.191, 194 Si NPs were released after etching the SiO2
15 matrix with HF, and then passivated with allylbenzene through
the thermally initiated hydrosilylation reaction. The resultant
colloidal Si NPs were fractionated by size selective precipitation
to obtain monodisperse nanoparticles, which showed strong
quantum confinement effects and size-dependent absolute QYs
191
20 (Figure 21).
The absolute QYs increased with particle size up
to 43%.
During preparation, Si NPs can be chemically doped to
introduce other functions.195, 196 Paramagnetic fluorescent Si NPs
were prepared by solvothermal decomposition of Mn-doped
195
25 sodium silicide.
The resultant Mn-doped Si NPs showed a
longitudinal relaxivity (r1) of 25.50 ± 1.44 mM-1s-1 and a
transverse relaxivity (r2) of 89.01 ± 3.26 mM-1s-1 under a
magnetic field of 1.4 T at 37 °C. Similarly, Fe-doped Si NPs were
prepared and exploited as bimodal imaging agents.196 The use of
30 reactive sodium silicide makes their control preparation difficult
and could limit their broad applications, and thus development of
novel preparation approaches is necessary.
Similar to carbon dots and GQDs, Si NPs produced from
different methods seem identical, but their optical properties are
35 dramatically different. For example, the Si NPs prepared with
high-temperature method routinely exhibit photoluminescence
agreeing with the effective mass approximation (EMA), while
those prepared via solution methods exhibit blue emission

Figure 22. (a) Photostability of Si NPs in comparison with
FITC, CdTe QDs and CdSe/ZnS QDs; (b) cell nuclei are
labeled by Si NPs (Left), microtubules are labeled by FITC
(middle); and superposition of the two fluorescence images
(right); (c) time-dependent stability comparison of
fluorescence signals of Hela cells labeled by Si NPs (blue)
and FITC (green). Reproduced from Ref. 204.
somewhat independent of particle size.197, 198 Recently, Dasog et
40 al. prepared Si NPs using three most widely cited procedures (i.e.
etching of annealed SiOx, reduction of SiCl4, and solvothermal
reaction of sodium silicide with NH4Br), 197 and found their
conversion of red-fluorescence to blue emission. Their findings
suggest that the presence of trace nitrogen and oxygen even at the
45 ppm level in Si NPs gives rise to the blue emission, and support
the hypothesis that the nitrogen defect or impurity site contributes
to the blue emission.197
In order to apply Si NPs to bioimaging, tremendous efforts
have been made to prepare water-soluble and biocompatible Si
199-205
50 NPs through simple and efficient methods.
For example, Si
NPs with excellent aqueous dispersibility, robust photo- and pHstability, strong fluorescence (∼15%), and favorable size (∼4 nm)
are facilely and rapidly prepared from Si nanowires and glutaric

acid in a short reaction time (e.g., 15 min) by He and coworkers.202 These Si NPs are particularly suitable for long-term
and real-time cellular imaging due to their higher photostability
than II-VI QDs and dyes (e.g. CdTe QDs and FITC). Distinctive
5 red fluorescence of Si NPs can be retained throughout 240-min
irradiation. In contrast, the green fluorescence of FITC rapidly
diminishes in 3 min due to severe photo bleaching, and the red
signals of CdTe QDs nearly vanishes after 25-min irradiation.
The MTT assays showed negligible cellular toxicity to HeLa
10 cells, demonstrating the excellent biocompatibility of Si NPs.
Furthering
their
research,
the
authors
used
(3aminopropyl)trimethoxylsiliane as precursor and prepared 2.2 nm
Si NPs by the similar method.204 The obtained Si NPs exhibited
strong green fluorescence with a QY of 20-25%,
15 biocompatibility, and robust photo- and pH-stability. As shown in
Figure 22, FITC, CdTe and CdSe/ZnS QDs, and Si NPs exhibited
distinct fluorescence behaviors during initial UV irradiation.204
The fluorescent signals of the former three samples were
gradually reduced with increasing irradiation time. The
20 fluorescence of FITC was completely quenched within 15 min
irradiation. In contrast, the Si NPs preserved stable and bright
fluorescence during long-time (e.g., 180 min) irradiation under
the same conditions. Figure 22c also shows that Si NPs-labelled
nuclei (blue) and the FITC-labelled cellular microtubules (green)
25 were intense and clearly spectrally resolved, respectively. The Si
NP-labelled nuclei retained stable fluorescence during
observation for 60 min, however the fluorescence from FITC
labels drastically decreased in 3 min due to severe photo
bleaching.
30
In addition to in vitro labelling cells, Si NPs can also be used
in multiple cancer-related in vivo applications, including tumor
vasculature targeting, sentinel lymph node mapping, and
multicolor NIR imaging in live mice.206 Erogbogbo and
coworkers demonstrated that Si NPs can overcome dispersibility
35 and functionalization challenges for in vivo imaging through
surface functionalization, PEGylated micelle encapsulation, and
bioconjugation process, which produced bright, targeted
nanospheres with stable luminescence and long (>40 h) tumor
accumulation time in vivo. Recently, the biodistribution and
40 toxicity of Si NPs in mice and monkeys have been assessed
(Figure 23).207 The top images in Figure 23 show the
biodistribution of Si NPs in mice, the fluorescence image of
frozen tissue sections, and the confocal images, which clearly
reveals particles localized in the liver, spleen, and kidneys after
45 injection. The ICP-MS data show notable increase of silicon
levels in the liver, spleen, lung, kidneys, and lymph. The
concentration of silicon in the lymph and kidneys declined over
the 14-week time period, while the liver and spleen retained a
significant fraction of the silicon injected, even after 14 weeks.207
50 There is no evidence of the biodegradability of silicon NPs. The
bottom images in Figure 23 display the histological images of the
brain, cerebellum, atrium, ventricle, heart muscle, lung, kidney,
liver, spleen, renal tubule, intestine, lymph nodes, and skin of the
rhesus macaques.207 There was no sign of nanoparticle-induced
55 changes in these organs and tissues. This research indicates
neither mice nor monkeys showed overt signs of toxicity
reflected in their behavior, body mass, or blood chemistry. The
biodistribution of Si NPs in mice was also quantitatively

Figure 23. (Top) biodistributions of Si NPs in mice assessed
by ICP-MS analysis, fluorescence images of frozen tissue
sections, confocal microscopy images; (bottom) histological
images of (a) brain, (b) heart, (c) liver, (d) spleen, (e) lung, (f)
kidney, (g) lymph, (h) intestine, and (i) skin harvested from
rhesus macaques administrated with Si NPs. Reproduced
from Ref. 207.
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evaluated by in vivo positron emission tomography (PET)
imaging and ex vivo gamma counting.208 A new macrocyclic
ligand-64Cu2+ complex was conjugated with dextran-coated Si
NPs and served as PET agent. The results show that conjugates
were excreted via renal filtration shortly post injection and also
accumulated in the liver, again demonstrating the stability and
biocompatibility of Si NPs.
In summary, Si NPs have tuneable fluorescence from visible to
near-infrared window, excellent biocompatibility, chemical, and
photostability. These properties make them very attractive in
bioimaging, however long-term studies on their safety and
adverse effects are still needed for their clinical applications.
7 Summary and outlook

75

We have summarized the current state of the art on ultra-small
inorganic nanoparticles for fluorescence bioimaging. These ultrasmall nanoparticles bridge the gap between big particles and
molecules. They have unique properties and great potential in

molecular imaging for diagnosis and treatment of cancer and
other diseases, as they could escape from macrophages, pass
biological barriers, and be easily degraded or excreted in
comparison with large particles.
5
The ultra-small fluorescent probes we addressed include the
conventional QDs, fluorescent metal nanoclusters, carbon-based
nanomaterials, up-conversion nanocrystals, and
silicon
nanoparticles. The fluorescence mechanisms in metal
nanoclusters, carbon dots, and graphene quantum dots are not
10 completely clear as yet. Although they can be prepared by
various wet chemistry methods, it remains a challenge to prepare
robust fluorescent probes with high photostability (i.e. nonblinking), chemical stability, high quantum yield, and tunable
emissions in the visible to NIR window. From the applications
15 perspective, some of them face the issue of toxicity, especially
semiconducting QDs and up-conversion nanocrystals, as they
have toxic elements such as cadmium and lanthanides. Various
approaches and coatings have been developed to modify and
functionalize their surfaces to overcome these shortcomings. In
20 addition to the issues of fluorescent nanoprobes themselves, there
are some important issues that have to be considered for practical
applications, including their interactions with proteins and other
biomolecules, their interactions with cells, their endocytosis and
intracellular stability and behaviour, and their metabolism and
25 excretion. These issues have not been well understood, despite
some progresses on bio-interface interactions in the biological
environments have been made in recent years.61-63
The use of fluorescence imaging alone could lead to inaccurate
diagnosis or misdiagnosis, due to the low spatial and temporal
30 resolution, and
the sensitivity of fluorescence to external
environments. Simultaneous use of multi-modal imaging (e.g.
magneto-fluorescence) could overcome the disadvantages of
individual methods. There are increasing reports on the
combination of fluorescence with other imaging methods such as
60, 209-212
35 MRI, CT, and PET.
There are few commercial
multifunctional instruments for multimodal imaging, however.
Relocating biological samples between different imaging
instruments could lead to inaccuracy.213 Development of
multimodal imaging that employs a single instrument is an
213
40 attractive solution.
In addition, incorporation of therapeutics
into multimodal nano-agents for early detection and treatment
will be an important feature of future nanotheranostics.
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